Science and Research

Effectiveness of Single Versus Multiple Inhaler Triple Therapy on Mortality and Cardiopulmonary Risk Reduction in COPD: The SKOPOS-MAZI Study

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) have elevated cardiopulmonary and mortality risk, particularly following exacerbations. While single inhaler triple therapies (SITTs), such as budesonide/glycopyrrolate/formoterol fumarate (BGF), reduce cardiopulmonary risk versus dual bronchodilator therapy, there is limited evidence comparing outcomes with SITTs versus multiple inhaler triple therapies (MITTs). METHODS: SKOPOS-MAZI was a retrospective comparative effectiveness study in patients with COPD aged

  • Pollack, M.
  • Rapsomaniki, E.
  • Anzueto, A.
  • Rhodes, K.
  • Hawkins, N. M.
  • Vogelmeier, C. F.
  • Marshall, J.
  • Müllerová, H.

Keywords

  • All-cause mortality
  • Budesonide/glycopyrrolate/formoterol fumarate
  • Cardiopulmonary
  • Chronic obstructive pulmonary disease
  • Comparative effectiveness study
  • Multiple inhaler triple therapy
  • Real-world evidence
  • Single inhaler triple therapy
Publication details
DOI: 10.1016/j.amjmed.2024.11.007
Journal: Am J Med
Work Type: Original
Location: UGMLC
Disease Area: COPD
Partner / Member: UMR
Access-Number: 39566703

DZL Engagements

chevron-down